NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/21/2023
Back to search
Official data from USPTO
BORA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
03/21/2023
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
11/04/2020
Registration date
03/21/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/21/2023
Last transaction
03/21/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
3
Owner type
99
Owner location
Taipei City, TW
Examiner
FRIEDMAN, LESLEE ANN
Law office
N20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the design of the stylized letters "BORA" underneath a cross within a square background.
Holders and representatives
Holders
BORA PHARMACEUTICALS CO., LTD.
Representatives
Hui Zhang RABIN & BERDO, P.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Nutritional supplements; Antiallergic medicines; Sulphonamides as medicines; Medicines for intestinal disorders; Medicines for dental purposes; Medicines for alleviating constipation; Motion sickness medicines; Medicines for the treatment of gastrointestinal diseases; Prescription and non-prescription medicinespillstabletscapsulescapletsliquid dropssachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Ocular pharmaceuticals; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Anti-diabetic pharmaceuticals; Pharmaceuticalspsychotropics; Pharmaceuticalsantihelmintics; Pharmaceuticalsanti-infectives; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticalsinducers of erections; Injectable pharmaceuticals for treatment of anaphylactic reactions; Pharmaceuticalslipid lowering agents; Antimicrobial preparations for inhibiting microbiological decomposition in foodbeveragesanimal feed and pharmaceuticals; Astringents for medicinal purposes; Pharmaceutical preparations for wounds; Dermatological pharmaceutical products; Pharmaceutical skin lotions; Pharmaceutical preparationsantivirals; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for skin care; Pharmaceutical preparationsantidepressants; Pharmaceutical preparations for use in urology; Pharmaceutical products and preparations for chloasma; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating diabetes; Pharmaceutical solutions used in dialysis; Pharmaceutical products for ophthalmological use; Anti-epileptic pharmaceutical preparations; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating hypertension; Pharmaceutical antitussive-cold preparations; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparationsanticoagulants; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating halitosis; Effervescent analgesic pharmaceutical preparations; Pharmaceutical products for the prevention and treatment of cancer; Analgesic and muscle relaxant pharmaceutical preparations; Pharmaceutical preparationsappetite suppressants; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting sensory organs; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparationsinjectable contraceptives; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products for the treatment of joint disease; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the relief of insect bites; Pharmaceutical preparations for the treatment of bone fractures; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for treating allergic rhinitis; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparationsan analgesic for human consumption taken orally; Pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical preparationsa topical preparation for the treatment of ocular disorders prescribed by ophthalmologistseye surgeonsoptometrists; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorderssports related injuriesfor knee cartilage regeneration; Pharmaceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disordersdiabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesfor the treatment of bacteria-based diseasesfor the treatment of diabetesanti-infective preparationsantiviral preparationsantibioticsantifungal preparations and vaccines; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary system; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for use in dermatologyoncologyhematology and in tissue and organ transplantationin ophthalmology and for gastroenterological disorders
Publications
History of USPTO decisions and trademark events.
39 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
03/21/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/03/2023
PUBO
PUBLISHED FOR OPPOSITION
01/03/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/14/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/30/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/09/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/09/2022
ALIE
ASSIGNED TO LIE
11/08/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
11/01/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/16/2022
GNSL
LETTER OF SUSPENSION E-MAILED
05/16/2022
CNSL
SUSPENSION LETTER WRITTEN
05/16/2022
DOCK
ASSIGNED TO EXAMINER
05/16/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/12/2022
ALIE
ASSIGNED TO LIE
05/12/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
05/10/2022
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
12/11/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
12/11/2021
CNSI
SUSPENSION INQUIRY WRITTEN
12/11/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
12/01/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
06/01/2021
GNSL
LETTER OF SUSPENSION E-MAILED
06/01/2021
CNSL
SUSPENSION LETTER WRITTEN
06/01/2021
DPCC
DIVISIONAL PROCESSING COMPLETE
05/24/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/20/2021
DRRR
DIVISIONAL REQUEST RECEIVED
04/28/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/28/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/28/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/28/2021
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
04/28/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/12/2021
GNRT
NON-FINAL ACTION E-MAILED
04/12/2021
CNRT
NON-FINAL ACTION WRITTEN
04/12/2021
DOCK
ASSIGNED TO EXAMINER
04/09/2021
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
01/05/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/04/2021
NWAP
NEW APPLICATION ENTERED
11/07/2020
Continuous trademark protection
Get notified about every new filing that threatens BORA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.